Funding round brings in $18M for inflammatory drug developer

04/8/2013 | MedCityNews.com

Aquinox Pharmaceuticals, which develops small-molecule therapies for inflammatory disorders, raised $18 million in a Series C funding round from investors including Pfizer and Johnson & Johnson's venture units. The firm says midstage trials of AQX-1125, its lead drug candidate, could begin within months in patients with chronic obstructive pulmonary disease and interstitial cystitis.

View Full Article in:

MedCityNews.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director of Behavioral Health Operations
Meridian Health Plan
Detroit, MI
Medical Director
PacificSource
Bend, OR
Clinical Appeals RN
MJHS
Brooklyn, NY
Director of Clinical Operations
Meridian Health Plan
Detroit, MI
Sr. Director, Regulatory Compliance Intelligence and Outreach
Johnson & Johnson
New Brunswick, NJ